To report the long-term significance of sentinel lymph node (SLN) biopsy on prognosis, determine false-negative SLN occurrences, and determine risk factors for death and recurrence in a large series of patients with head and neck melanoma.
Study Design
Case series with tumor registry review.
Setting
Academic tertiary care medical center.
Subjects and Methods
A database review was performed of all patients who underwent SLN biopsy for head and neck melanoma from 1994 to 2009. End points assessed were SLN status, recurrence, false-negative SLN results, and survival comparing SLN-positive and SLN-negative patients and different locations. Survival curves and multivariate analyses were performed.
Results
SLN biopsy was performed in 365 patients. SLNs were identified in 98.6% of patients with a mean of 3.7 nodes removed from 1.6 nodal basins per patient. Median follow-up was 8 years. The SLN was positive in 40 (11%) patients. SLN–positive patients had significantly thicker melanomas, higher recurrence (P < .0001), and a significant decrease in overall survival compared with SLN-negative patients (P < .002). Scalp melanoma patients had significantly thicker melanomas and an elevated risk of SLN positivity, recurrence, and death compared with other sites. Seventeen of 365 SLN-negative patients developed regional nodal disease for a false-omission rate of 5.2% and a negative predictive value of a negative SLN to be 94.8%. Risks for false negative-SLN occurrences included thick melanomas and scalp melanomas.
Conclusion
SLN biopsy is accurate in head and neck melanoma and provides significant prognostic data. Scalp melanoma patients present with thicker tumors with an increase in SLN positivity and false-negative SLN occurrences.
LeongSPL. Role of selective sentinel lymph node dissection in head and neck melanoma. J Surg Oncol. 2011;104:361-368.
2.
UristMMBalchCMSoongSJ. Head and neck melanoma in 534 clinical stage 1 patients: a prognostic factor analysis and results of surgical treatment. Ann Surg. 1984;200:769-775.
3.
O’BrienCJCoatesASPetersen-SchaeferK. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg. 1991;162:310-314.
4.
WaneboHJCooperPHYoungDV. Prognostic factors in head and neck melanoma: effect of lesion location. Cancer. 1988;62:831-837.
5.
NarayanDAriyanS. Surgical considerations in the management of malignant melanoma of the ear. Plast Reconstr Surg. 2001;107:20-24.
6.
AugusteLJBellucoCPeraloJLiseM. Surgical management of BANS malignant melanoma. Surgery. 1991;110:598-602.
7.
FisherSR. Cutaneous malignant melanoma of the head and neck. Laryngoscope. 1989;99:822-836.
8.
LachiewiczAMBerwickMWigginsCL. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol. 2008;144:515-521.
9.
LeongSPAccorttNAEssnerR. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg. 2006;132:370-373.
10.
EberbachMAWahlRLArgentaLC. Utility of lymphoscintigraphy in directing surgical therapy for melanomas of the head, neck, and upper thorax. Surgery. 1987;102:433-442.
11.
O’BrienCJUrenRFThompsonJF. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg. 1995;170:461-466.
12.
LinDFrancBLKashani-SabetMSingerMI. Lymphatic drainage patterns of the head and neck: cutaneous melanoma observed on lymphoscintigraphy and sentinel lymph node biopsy. Head Neck. 2006;28:249-255.
13.
LeongSPAchtemTAHabibFA. Discordance between clinical predictions vs. lymphoscintigraphic and intraoperative mapping of sentinel lymph node drainage of primary melanoma. Arch Dermatol. 1999;135:1472-1476.
14.
PathakIO’BrienCJPetersen-SchaefferK. Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern?Head Neck. 2001;23:785-790.
15.
BalchCMGershenwaldJESoongSJ. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
16.
LeongSP. Sentinel lymph node mapping and selective lymphadenectomy: the standard of care for melanoma. Curr Treat Options Oncol. 2004;5:185-194.
17.
MortonDLThompsonJFCochranAJ. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
18.
SaltmanBEGanlyIPatelSG. Prognostic implication of sentinel lymph node biopsy in cutaneous head and neck melanoma. Head Neck. 2010;32:1686-1692.
19.
de RosaNLymanGHSilberminsD. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg. 2011;145:375-382.
20.
JansenLKoopsHSNiewegOE. Sentinel node biopsy for melanoma in the head and neck region. Head Neck. 2000;22:27-33.
21.
SchmalbachCENussenbaumBReesRSSchwartzJJohnsonTMBradfordCR. Reliability of sentinel lymph node mapping with biopsy for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg. 2003;129:61-65.
22.
EicherSAClaymanGLMyersJNGillenwaterAM. A prospective study of intraoperative lymphatic mapping for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg. 2002;128:241.
23.
MacNeillKNGhazarianDMcCreadyDRotsteinL. Sentinel lymph node biopsy for cutaneous melanoma of the head and neck. Ann Surg Oncol. 2005;12:726-732.
24.
PatelSGCoitDGShahaAR. Sentinel lymph node biopsy for cutaneous head and neck melanomas. Arch Otolaryngol Head Neck Surg. 2002;128:285-291.
25.
TanisPJNiewegOEvan den BrekelMWBalmAJ. Dilemma of clinically node-negative head and neck melanoma: outcome of “watch and wait” policy, elective lymph node dissection, and sentinel node biopsy—a systematic review. Head Neck. 2008;30:380-389.
26.
ErmanABCollarRMGriffithKA. Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer. 2011;18:3593-3600.
27.
JensenJDGrayRJWasifN. Can lymphatic drainage of head and neck melanoma be predicted?J Surg Oncol. 2011;103:751-755.
28.
ValsecchiMESilberminsDde RosaNWongSLLymanGH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29:1479-1487.
29.
CarlsonGWMurrayDRLylesRHHestleyACohenC. Sentinel lymph node biopsy in the management of cutaneous head and neck melanoma. Plastic Reconstr Surg. 2005;115:721-728.
30.
WagnerJDParkHMColemanJJIIILoveCHayesJT. Cervical sentinel lymph node biopsy for melanomas of the head and neck and upper thorax. Arch Otolaryngol Head Neck Surg. 2000;126:313-321.
31.
FincherTRO’BrienJCMcCartyTM. Patterns of drainage and recurrence following sentinel lymph node biopsy for cutaneous melanoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2004;130:844-848.
32.
DayCLJrMihmMCJrSoberAJJr. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness: an appraisal of “thin” level IV lesions. Ann Surg. 1982;195:30-34.
33.
LiuLCParrettBMJenkinsT. Selective sentinel lymph node dissection for melanoma importance of harvesting nodes with lower radioactive counts without the need for blue dye. Ann Surg Oncol. 2011;18:2919-2924.
34.
TreselerPATauchiPS. Pathologic analysis of the sentinel lymph node. Surg Clin North Am. 2000;80:1695-1719.
35.
WhiteRLJrAyersGDStellVH. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol. 2011;18:3593-3600.
36.
ChaoCWongSLEdwardsMJ. Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol. 2003;10:21-26.
37.
MillerMWVettoJTMonroeMMWeerasingheRAndersenPEGrossND. False-negative sentinel lymph node biopsy in head and neck melanoma. Otolaryngol Head Neck Surg. 2011;145:606-611.
38.
AzzolaMFShawHMThompsonJF. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498.
39.
AmersiFMortonDL. The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg. 2007;41:241-256.
40.
CloseLGGoepfertHBallantyneAJJesseRH. Malignant melanoma of the scalp. Laryngoscope. 1979;89:1189-1196.
41.
PanWRLe RouxCMBriggsCA. Variations in the lymphatic drainage pattern of the head and neck: further anatomic studies and clinical implications. Plast Reconstr Surg. 2011;127:611-620.
42.
MortonDLThompsonJFEssnerR. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999;230:453-463.
43.
NoweckiZIRutkowskiPNasierowska-GuttmejerARukaW. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13:1655-1663.
44.
VeenstraHJWoutersMJKroonBB. Less false-negative sentinel node procedures in melanoma patients with experience and proper collaboration. J Surg Oncol. 2011;104:454-457.
45.
McMastersKMReintgenDSRossMI. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?Ann Surg Oncol. 2001;8:192-197.
46.
KapteijnBANiewegOELiemI. Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol. 1997;4:156-160.
47.
GennariRBartolomeiMTestoriA. Sentinel node localization in primary melanoma: preoperative dynamic lymphoscintigraphy, intraoperative gamma probe, and vital dye guidance. Surgery. 2000;127:19-25.
48.
LeongSPDoneganEHeffernonW. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000;7:361-366.
